Jankevicius F - Search Results

1

p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.

Jankevicius F, Goebell P, Kushima M, Schulz WA, Ackermann R, Schmitz-Dräger BJ. Jankevicius F, et al. Urol Int. 2002;69(3):174-80. doi: 10.1159/000063949. Urol Int. 2002. PMID: 12372883

2

[Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].

Schmitz-Dräger BJ, Jankevicius F, Otto T. Schmitz-Dräger BJ, et al. Among authors: jankevicius f. Urologe A. 1995 May;34(3):195-9. Urologe A. 1995. PMID: 7610511 Review. German.

3

Dual-parameter immunoflow cytometry--a new technique in the noninvasive diagnosis of bladder cancer.

Jankevicius F, Shibayama T, Decken K, Bojar H, Ebert T, Ackermann R, Schmitz-Dräger BJ. Jankevicius F, et al. Urol Int. 1995;55(2):68-73. doi: 10.1159/000282754. Urol Int. 1995. PMID: 8533198

4

Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Schmitz-Dräger BJ, Jankevicius F, Ackermann R. Schmitz-Dräger BJ, et al. Among authors: jankevicius f. World J Urol. 1996;14(3):190-6. doi: 10.1007/BF00186899. World J Urol. 1996. PMID: 8806198 Review.

5

Predictive value of molecular alterations for the prognosis of urothelial carcinoma.

Schulz WA, Jankevicius F, Gerharz CD, Kushima M, van Roeyen C, Bültel H, Göbell P, Schmitz-Dräger BJ. Schulz WA, et al. Among authors: jankevicius f. Cancer Detect Prev. 1998;22(5):422-9. doi: 10.1046/j.1525-1500.1998.00048.x. Cancer Detect Prev. 1998. PMID: 9727623

6

Dual-parameter immunoflow cytometry in diagnosis and follow-up of patients with bladder cancer.

Jankevicius F, Shibayama T, Decken K, Bojar H, Gerharz CD, Ebert T, Ackermann R, Schmitz-Dräger BJ. Jankevicius F, et al. Eur Urol. 1998 Dec;34(6):492-9. doi: 10.1159/000019789. Eur Urol. 1998. PMID: 9831791

7

Nutrition and risk of prostate cancer.

Jankevicius F, Miller SM, Ackermann R. Jankevicius F, et al. Urol Int. 2002;68(2):69-80. doi: 10.1159/000048422. Urol Int. 2002. PMID: 11834894 Review. No abstract available.

8

Nephron sparing surgery in renal cancer--individual decision or standard procedure?

Schmitz-Dräger BJ, Beiche B, Fischer C, Jankevicius F, Ebert T. Schmitz-Dräger BJ, et al. Among authors: jankevicius f. Actas Urol Esp. 2003 Jan;27(1):10-7. Actas Urol Esp. 2003. PMID: 12701492 Review.

9

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.

Lotan Y, Shariat SF, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Lotan Y, et al. Among authors: jankevicius f. Urol Oncol. 2010 Jul-Aug;28(4):441-8. doi: 10.1016/j.urolonc.2009.11.004. Urol Oncol. 2010. PMID: 20610281

10

Role of marker lesion when applying intravesical instillations of IL-2 for non-muscle-invasive bladder cancer comparison of the therapeutic effects in two pilot studies.

Den Otter W, Van Moorselaar RJ, Jacobs JJ, Haar RT, Koten JW, Dobrowolski Z, Lipczynski W, Pašukonienė V, Characiejus D, Jankevičius F, Eidukevičius R, De Reijke TM. Den Otter W, et al. Among authors: jankevicius f. Anticancer Res. 2013 May;33(5):2099-105. Anticancer Res. 2013. PMID: 23645761

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

69 results

Search Page

Filters